Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Proteomics
  4. Fast Track Articles
  5. Fast Track Article
image of Identifying Prostaglandin D2 Synthase in Urine: A Potential Biomarker for Bladder Cancer

Abstract

Introduction

Proteins present in body fluids harbor the potential to act as markers for both diagnosing diseases and exploring their underlying mechanisms. As urine can be easily obtained non-invasively, analyzing its proteins is an ideal approach to identifying biomarkers for bladder cancer. This study aimed to identify proteins in urine that could serve as biomarkers for bladder cancer.

Method

Urine samples were collected from patients with primary transitional cell carcinoma of the bladder and their age and sex-matched healthy individuals. The protein pellet underwent resolubilization and trypsin digestion to facilitate analysis using reverse phase nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry.

Result

In samples obtained from 16 patients and 8 controls, 3192 peptides were identified, corresponding to 934 unique proteins, of which 60 were identified with higher confidence levels. Among them, Transferrin and Prostaglandin D2 Synthase (PTGDS) were found as potential markers of bladder cancer. In particular, the absence of PTGDS has a specificity of 100% and a sensitivity of 81%.

Conclusion

This study, which used proteomic approaches, identified PTGDS in urine as a potential biomarker of bladder cancer.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cp/10.2174/0115701646315079240919085008
2024-10-03
2025-04-06

  • From This Site

    /content/journals/cp/10.2174/0115701646315079240919085008
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Vlahou A. Schellhammer P.F. Mendrinos S. Patel K. Kondylis F.I. Gong L. Nasim S. Wright G.L. Jr Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001 158 4 1491 1502 10.1016/S0002‑9440(10)64100‑4 11290567
    [Google Scholar]
  2. Shokeir A.A. Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment. BJU Int. 2004 93 2 216 220 10.1111/j.1464‑410X.2004.04588.x 14690486
    [Google Scholar]
  3. Fleshner N.E. Herr H.W. Stewart A.K. Murphy G.P. Mettlin C. Menck H.R. The National cancer data base report on bladder carcinoma. Cancer 1996 78 7 1505 1513 8839558
    [Google Scholar]
  4. Zhang J. Zheng S. Gao Y. Rotolo J.A. Xiao Z. Li C. Cheng S. A partial allelotyping of urothelial carcinoma of bladder in the Chinese. Carcinogenesis 2003 25 3 343 347 10.1093/carcin/bgh015 14604888
    [Google Scholar]
  5. Underwood W. III Dunn R.L. Williams C. Lee C.T. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. J. Am. Coll. Surg. 2006 202 2 284 290 10.1016/j.jamcollsurg.2005.09.009 16427554
    [Google Scholar]
  6. Têtu B. Tiguert R. Harel F. Fradet Y. ImmunoCyt/uCyt+™ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod. Pathol. 2005 18 1 83 89 10.1038/modpathol.3800262 15389253
    [Google Scholar]
  7. American Joint committee on Cancer Manual for staging of cancer. Beahrs OA. Henson DE. Hutter RVP. Myers MH.
    [Google Scholar]
  8. Mostifi F.K. Histological typing of urinary bladder tumours. 1973 Available from: https://iris.who.int/handle/10665/41533
  9. Bradford M.M. A rapid and sensitive method for the quantities of protein. Anal. Biochem. 1976 72 248 254 10.1016/0003‑2697(76)90527‑3 942051
    [Google Scholar]
  10. Washburn M.P. Wolters D.A. Yates J.R. Large- scale analysis of the yeast proteome by multidimentional technology. Nat. Biotechnol. 2001 19 242 247 10.1038/85686 11231557
    [Google Scholar]
  11. Tyan Y.C. Guo H.R. Liu C.Y. Liao P.C. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Chim. Acta 2006 579 2 158 176 10.1016/j.aca.2006.07.033 17723740
    [Google Scholar]
  12. Oh J. Pyo J.H. Jo E.H. Hwang S.I. Kang S.C. Jung J.H. Park E.K. Kim S.Y. Choi J.Y. Lim J. Establishment of a near‐standard two‐dimensional human urine proteomic map. Proteomics 2004 4 11 3485 3497 10.1002/pmic.200401018 15529407
    [Google Scholar]
  13. Pieper R. Gatlin C.L. McGrath A.M. Makusky A.J. Mondal M. Seonarain M. Field E. Schatz C.R. Estock M.A. Ahmed N. Anderson N.G. Steiner S. Characterization of the human urinary proteome: A method for high‐resolution display of urinary proteins on two‐dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004 4 4 1159 1174 10.1002/pmic.200300661 15048996
    [Google Scholar]
  14. Pang J.X. Ginanni N. Dongre A.R. Hefta S.A. Opiteck G.J. Biomarker discovery in urine by proteomics. J. Proteome Res. 2002 1 2 161 169 10.1021/pr015518w 12643536
    [Google Scholar]
  15. Thongboonkerd V. Mcleish K.R. Arthur J.M. Klein J.B. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002 62 4 1461 1469 10.1111/j.1523‑1755.2002.kid565.x 12234320
    [Google Scholar]
  16. Seymour G.J. Walsh M.D. Lavin M.F. Strutton G. Gardiner R.A. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol. Res. 1987 15 6 341 344 10.1007/BF00265663 3324443
    [Google Scholar]
  17. Schmetter B.S. Habicht K.K. Lamm D.L. Morales A. Bander N.H. Grossman H.B. Hanna M.G. Jr Silberman S.R. Butman B.T. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J. Urol. 1997 158 3 801 805 10.1016/S0022‑5347(01)64321‑0 9258086
    [Google Scholar]
  18. Stein J.P. Grossfeld G.D. Ginsberg D.A. Esrig D. Freeman J.A. Figueroa A.J. Skinner D.G. Cote R.J. Prognostic markers in bladder cancer: A contemporary review of the literature. J. Urol. 1998 160 645 659 10.1097/00005392‑199809010‑00003 9720515
    [Google Scholar]
  19. Konety B.R. Nguyen T.S.T. Brenes G. Sholder A. Lewis N. Bastacky S. Potter D.M. Getzenberg R.H. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J. Urol. 2000 164 634 639 10.1016/S0022‑5347(05)67269‑2 10953114
    [Google Scholar]
  20. Chakraborty A. Dasari S. Long W. Mohan C. Urine protein biomarkers for the detection, surveillance, and treatment response prediction of bladder cancer. Am. J. Cancer Res. 2019 9 6 1104 1117 31285945
    [Google Scholar]
  21. Grossman H.B. New methods for detection of bladder cancer. Semin. Urol. Oncol. 1998 16 1 17 22 9508078
    [Google Scholar]
  22. Ianari A. Sternberg C.N. Rossetti A. Van Rijn A. Deidda A. Giannarelli D. Pansadoro V. Results of bard bta test in monitoring patients with a history of transitional cell cancer of the bladder. Urology 1997 49 5 786 789 10.1016/S0090‑4295(97)00081‑2 9145993
    [Google Scholar]
  23. Pirtskalaishvili G. Konety B.R. Getzenberg R.H. Update on urine-based markers for bladder cancer. Postgrad. Med. 1999 106 6 85 94 10.3810/pgm.1999.11.774
    [Google Scholar]
  24. Sarosdy M.F. deVere White R.W. Soloway M.S. Sheinfeld J. Hudson M.A. Schellhammer P.F. Jarowenko M.V. Adams G. Blumenstein B.A. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol. 1995 154 2 379 384 10.1016/S0022‑5347(01)67054‑X 7609102
    [Google Scholar]
  25. Sharma S. Zippe C.D. Pandrangi L. Nelson D. Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J. Urol. 1999 162 1 53 57 10.1097/00005392‑199907000‑00014 10379739
    [Google Scholar]
  26. Vanarsa K. Enan S. Patel P. Strachan B. Sam Titus A.S.C.L. Dennis A. Lotan Y. Mohan C. Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens. Oncotarget 2021 12 8 783 790 10.18632/oncotarget.27941 33889301
    [Google Scholar]
  27. Hurley L. Siroky MB. Edelsttein RA. Krene RJ. Neoplasms of the genitourinary tract. Manual of urology: Diagnosis and therapy Lippincott Williams & Wilkins 1999
    [Google Scholar]
  28. Spahr C.S. Davis M.T. McGinley M.D. Robinson J.H. Bures E.J. Beierle J. Mort J. Courchesne P.L. Chen K. Wahl R.C. Yu W. Luethy R. Patterson S.D. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry I.Profiling an unfractionated tryptic digest. Proteomics 2001 1 1 93 107 11680902
    [Google Scholar]
  29. Heine G. Raida M. Forssmann W.G. Mapping of peptides and protein fragments in human urine using liquid chromatography–mass spectrometry. J. Chromatogr. A 1997 776 1 117 124 10.1016/S0021‑9673(97)00440‑8 9286085
    [Google Scholar]
  30. Johansson B. Urinary protein patterns in patients with uroepithelial tumours. Effect of surgery and radiotherapy. Scand. J. Urol. Nephrol. 1975 9 3 221 225 10.3109/00365597509134216 1209177
    [Google Scholar]
  31. Hemmingsen L. Rasmussen F. Skaarup P. Wolf H. Urinary protein profiles in patients with urothelial bladder tumours. Br. J. Urol. 1981 53 4 324 329 10.1111/j.1464‑410X.1981.tb03189.x 7260547
    [Google Scholar]
  32. Johansson B. Kistner S. Proteinuria in patients with uroepithelial tumours with special regard to tumour size, clinical staging and grade of malignancy. Scand. J. Urol. Nephrol. 1975 9 1 45 49 10.3109/00365597509139913 1215844
    [Google Scholar]
  33. Hayashi O. Noguchi S. Oyasu R. Transferrin as a growth factor for rat bladder carcinoma cells in culture. Cancer Res. 1987 47 17 4560 4564 3621154
    [Google Scholar]
  34. Guo M. Sun H. McArdle H.J. Gambling L. Sadler P.J. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry 2000 39 33 10023 10033 10.1021/bi000798z 10955990
    [Google Scholar]
  35. Huebers H.A. Finch C.A. The physiology of and receptors. Physiol. Rev. 1987 67 520 525 10.1152/physrev.1987.67.2.520 3550839
    [Google Scholar]
  36. Whitney J.F. Clark J.M. Griffin T.W. Gautam S. Leslie K.O. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates. Cancer 1995 76 1 20 25 8630872
    [Google Scholar]
  37. Vandewalle B. Granier A.M. Peyrat J.P. Bonneterre J. Lefebvre J. Transferrin receptors in cultured breast cancer cells. J. Cancer Res. Clin. Oncol. 1985 110 1 71 76 10.1007/BF00402505 2991295
    [Google Scholar]
  38. Ikuta K. Fujimoto Y. Suzuki Y. Tanaka K. Saito H. Ohhira M. Sasaki K. Kohgo Y. Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells. Biochim. Biophys. Acta Mol. Cell Res. 2000 1496 2-3 221 231 10.1016/S0167‑4889(00)00016‑1 10771090
    [Google Scholar]
  39. Shibata T. Kondo M. Osawa T. Shibata N. Kobayashi M. Uchida K. 15-Deoxy-5-12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory process. J. Biol. Chem. 2002 277 10459 10466 10.1074/jbc.M110314200 11786541
    [Google Scholar]
  40. Clay C.E. Namen A.M. Atsumi G. Willingham M.C. High K.P. Kute T.E. Trimboli A.J. Fonteh A.N. Dawson P.A. Chilton F.H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999 20 10 1905 1911 10.1093/carcin/20.10.1905 10506103
    [Google Scholar]
  41. Callejas N.A. Castrillo A. Boscá L. Martín-Sanz P. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators. J. Pharmacol. Exp. Ther. 1999 288 3 1235 1241 10027864
    [Google Scholar]
  42. Kikuchi Y. Miyauchi M. Oomori K. Kita T. Kizawa I. Kato K. Inhibition of human ovarian cancer cell growth in vitro and in nude mice by prostaglandin D2. Cancer Res. 1986 46 7 3364 3366 3458525
    [Google Scholar]
  43. Nithipatikom K. Isbell M.A. Lindholm P.F. Kajdacsy-Balla A. Kaul S. Campell W.B. Requirement of cyclooxygenese-2 expression and prostaglandin for human prostate cancer cell invasion. Clin. Exp. Metastasis 2002 19 7 593 601 10.1023/A:1020915914376 12498388
    [Google Scholar]
  44. Chinetti G. Griglio S. Antonucci M. Torra I.P. Delerive P. Majd Z. Fruchart J.C. Chapman J. Najib J. Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 1998 273 40 25573 25580 10.1074/jbc.273.40.25573 9748221
    [Google Scholar]
  45. Friedrich M.G. Hellstern A. Hautmann S.H. Graefen M. Conrad S. Huland E. Huland H. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: A comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J. Urol. 2002 168 2 470 474 10.1016/S0022‑5347(05)64660‑5 12131290
    [Google Scholar]
  46. Diamandis E.P. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin. Chem. 2004 50 5 793 795 10.1373/clinchem.2004.032177 15105344
    [Google Scholar]
  47. Patton S.E. Hall M.C. Ozen H. Bladder cancer. Curr. Opin. Oncol. 2002 14 3 265 272 10.1097/00001622‑200205000‑00003 11981270
    [Google Scholar]
  48. Ellis W.J. Blumenstein B.A. Ishak L.M. Enfield D.L. Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumors. Urology 1997 50 6 882 887 10.1016/S0090‑4295(97)00508‑6 9426718
    [Google Scholar]
  49. Kausch I. Böhle A. Bladder Cancer. Eur. Urol. 2001 39 5 498 506 10.1159/000052495 11464029
    [Google Scholar]
/content/journals/cp/10.2174/0115701646315079240919085008
Loading
Identifying Prostaglandin D2 Synthase in Urine: A Potential Biomarker for Bladder Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0115701646315079240919085008
/content/journals/cp/10.2174/0115701646315079240919085008
/content/journals/cp/10.2174/0115701646315079240919085008
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keywords: urine ; mass spectrometry ; biomarker ; bladder cancer ; Proteome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test